Moderna gets nod to fill up to 15 doses per vial of its COVID-19 vaccine
Reuters
Published Apr 01, 2021 22:32
(Reuters) - Moderna Inc on Thursday received approval from the U.S. Food and Drug Administration (FDA) for an additional multi-dose vial of its COVID-19 vaccine in which each vial contains a maximum of 15 doses, increasing the number of doses available.
The agency also revised the number of doses per vial from its currently available vials to a maximum of 11 doses from 10.
U.S. distribution of Moderna's COVID-19 vaccine began in December following the FDA's emergency use authorization, and the company has shipped 100 million doses of its vaccine to the United States as of March. 29
Moderna expects to begin shipping of its 15-dose vials in the coming weeks.
Separately, U.S. top infectious diseases doctor Anthony Fauci told Reuters on Thursday that the country may not need AstraZeneca (NASDAQ:AZN)'s COVID-19 vaccine, even if it wins U.S. regulatory approval.
Get The App
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.